Shanghai Pharma Manufacturing Halves In April

US Congress Questions China-Only Clinical Data Quality

China's main pharma hub of Shanghai reported sector output has plunged by more than half due in large part to the prolonged lockdown, while 58% of surveyed foreign companies in China across all industries project declining revenue.

Shanghai residents line up to get COVID-19 vaccines in January 2022
SHANGHAI RESIDENTS QUEUE FOR COVID VACCINE SHOTS IN JANUARY 2022 • Source: Shutterstock

The latest statistics from Shanghai show China’s pharmaceutical industry hub saw the output of its operations in the sector plunge in April, largely impacted by the strict lockdowns imposed in the city since late March.

Two months later, the metropolis is preparing to reopen but this may take much longer than anticipated.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from China

More from Focus On Asia